Welcome to our dedicated page for Mersana Therapeutics news (Ticker: MRSN), a resource for investors and traders seeking the latest updates and insights on Mersana Therapeutics stock.
Mersana Therapeutics Inc (MRSN) is a clinical-stage biopharmaceutical pioneer developing antibody-drug conjugates (ADCs) through its proprietary Fleximer platform. This page serves as the definitive source for verified news and regulatory updates about their innovative cancer therapies.
Investors and researchers will find timely updates on clinical trial progress, partnership announcements, and scientific advancements across MRSN's ADC platforms. Our curated feed includes press releases about Dolasynthen payload optimization, Immunosynthen immune activation studies, and strategic collaborations advancing oncology pipeline candidates.
All content undergoes strict verification to ensure accuracy in reporting trial phases, regulatory milestones, and business developments. Bookmark this page for centralized access to MRSN's latest ADC research breakthroughs, presented with context for both professional investors and therapeutic area specialists.
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, at 2:00 p.m. ET, and deliver a presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 2:00 p.m. ET. Both events will be webcast live and available on Mersana's website, with replays accessible for approximately 90 days.
Mersana Therapeutics (NASDAQ: MRSN) announced upcoming presentations of their B7-H4-directed Dolasynthen ADC, emiltatug ledadotin (Emi-Le), at the ASCO 2025 Annual Meeting from May 30-June 3, 2025. The presentations include:
1. An oral presentation on Phase 1 dose escalation data across tumor types by Dr. Erika Hamilton on June 2, 2025
2. A poster presentation on the ongoing Phase 1 dose expansion trial in triple negative breast cancer (TNBC) patients by Dr. Hyo Han
Initial clinical data from December 2024 showed Emi-Le was generally well tolerated with confirmed objective responses across all enrolled tumor types. The FDA has granted two Fast Track designations for Emi-Le: one for advanced/metastatic TNBC and another for HER2 low/negative breast cancer patients who received prior topo-1 ADC treatment.
Mersana Therapeutics (NASDAQ:MRSN) has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company granted a restricted stock unit (RSU) award to one new employee who joined in March 2025. The award consists of 26,790 shares of common stock.
The RSU award will vest in four equal annual installments starting from February 15, 2025, contingent on the employee's continued service with Mersana. The grant is subject to Mersana's 2022 Inducement Stock Incentive Plan and RSU agreement terms.
Mersana Therapeutics (NASDAQ: MRSN) announced upcoming presentation of Phase 1 clinical data for emiltatug ledadotin (Emi-Le) at ESMO Breast Cancer 2025 Annual Congress in Munich. The presentation will focus on clinical activity in patients with triple negative breast cancer (TNBC) who received prior topoisomerase-1 inhibitor ADC treatment.
Initial clinical data from December 13, 2024, showed Emi-Le was generally well-tolerated with a differentiated safety profile. The B7-H4-directed Dolasynthen ADC demonstrated confirmed objective responses across all enrolled tumor types. The FDA has granted two Fast Track designations for Emi-Le: one for advanced/metastatic TNBC and another for advanced/metastatic breast cancer in patients with HER2-low or HER2-negative disease who received prior topo-1 ADC.
Mersana Therapeutics (NASDAQ: MRSN) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical development programs. The company announced positive initial Phase 1 data for Emi-Le, its B7-H4-targeting ADC candidate, and received an additional Fast Track designation from the FDA.
Key financial metrics for Q4 2024:
- Cash position: $134.6 million as of December 31, 2024
- Collaboration revenue: $16.4 million (up from $10.7 million in Q4 2023)
- Net loss: $14.1 million ($0.11 per share)
- R&D expenses: $22.3 million
- G&A expenses: $8.9 million
For full year 2024, the company reported collaboration revenue of $40.5 million and a net loss of $69.2 million ($0.56 per share). Mersana expects its current capital resources to support operations into 2026.
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment in areas of high unmet medical need, has announced its participation in two upcoming investor conferences.
Management will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 1:50 p.m. Eastern Time in a presentation/fireside chat format. Additionally, they will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time.
Both events will be available via live webcasts on the Investors & Media section of Mersana's website (www.mersana.com), with archived replays accessible for approximately 90 days after the events.
FAQ
What is the current stock price of Mersana Therapeutics (MRSN)?
What is the market cap of Mersana Therapeutics (MRSN)?
